|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500114496 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-12 17:18:41 |
|
注册时间: Date of Registration: |
2025-12-12 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
鹦鹉热衣原体肺炎真实世界前瞻性队列研究:重症危险因素与抗菌药物比较效果评价 |
|
Public title: |
Prospective Cohort Study of Psittacosis Pneumonia in the Real World: Evaluation of Risk Factors for Severe Disease and Comparative Effectiveness of Antibiotics |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
鹦鹉热衣原体肺炎真实世界前瞻性队列研究:重症危险因素与抗菌药物比较效果评价 |
|
Scientific title: |
Prospective Cohort Study of Psittacosis Pneumonia in the Real World: Evaluation of Risk Factors for Severe Disease and Comparative Effectiveness of Antibiotics |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
树欣晨 |
研究负责人: |
冯旰珠 |
|
Applicant: |
Shu Xinchen |
Study leader: |
Feng Ganzhu |
|
申请注册联系人电话: Applicant telephone: |
+86 198 2263 0975 |
研究负责人电话: Study leader's telephone: |
+86 189 5176 2691 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
19822630975@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhu1635253@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国江苏省南京市鼓楼区建宁路200号 |
研究负责人通讯地址: |
中国江苏省南京市鼓楼区姜家园121号 |
|
Applicant address: |
200 Jianning Road, Gulou District, Nanjing, Jiangsu,China |
Study leader's address: |
121 Jiangjiayuan, Gulou District, Nanjing, Jiangsu, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京医科大学 |
||
|
Applicant's institution: |
Nanjing Medical University |
||
|
研究负责人所在单位: |
南京医科大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Nanjing Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-KY-489-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京医科大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
The Medical Ethics Committee of the Second Affiliated Hospital of Nanjing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-26 00:00:00 |
||
|
伦理委员会联系人: |
韩婷 |
||
|
Contact Name of the ethic committee: |
Han Ting |
||
|
伦理委员会联系地址: |
中国江苏省南京市鼓楼区姜家园121号 |
||
|
Contact Address of the ethic committee: |
121 Jiangjiayuan, Gulou District, Nanjing, Jiangsu, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 5850 9670 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京医科大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Nanjing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国江苏省南京市鼓楼区姜家园121号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
121 Jiangjiayuan, Gulou District, Nanjing, Jiangsu, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
南京医科大学第二附属医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
The Second Affiliated Hospital of Nanjing Medical University |
||||||||||||||||||||||
|
Target disease: |
Psittacosis pneumonia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
探明真实世界中鹦鹉热衣原体肺炎患者进展至重症的危险因素,并比较四环素类 vs 喹诺酮类抗菌药物达到临床稳定的时间差异。 |
||||||||||||||||||||||
|
Objectives of Study: |
To identify the risk factors for progression to severe disease in patients with psittacosis pneumonia in the real world, and to compare the time to clinical stability between tetracycline and quinolone antibiotics. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄>=18岁; 2.符合社区获得性肺炎诊断,且mNGS或PCR证实Chlamydia psittaci阳性; 3.胸部影像证实肺炎; 4.住院时间>=24小时。 5.签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged >=18 years; 2. Meet the diagnostic criteria for community-acquired pneumonia, with Chlamydia psittaci positivity confirmed by mNGS or PCR; 3. Chest imaging confirms pneumonia; 4. Hospitalization duration >=24 hours. 5. Sign the informed consent form |
||||||||||||||||||||||
|
排除标准: |
1.妊娠或哺乳; 2.合并其他明确病原体(细菌、真菌、结核)的混合感染; 3.入院24小时内自动出院或死亡; 4.关键临床资料缺失>30%。 5.研究者判断不适合纳入 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Pregnant or breastfeeding; 2.Combined with mixed infections of other definite pathogens (bacteria, fungi, tuberculosis); 3.Discharged or deceased within 24 hours of admission; 4.Missing more than 30% of key clinical data. 5. The investigator determines that inclusion is not appropriate. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-12-31 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-01-01 00:00:00 至 To 2026-09-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后一年内;ResMan(http://www.medresman.org.cn/) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Within one year after the conclusion of the research;ResMan(http://www.medresman.org.cn/) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |